Analyzing...
Loading company...
Concord Biotech Ltd is a IN-based company operating in Pharmaceuticals industry. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2023-08-18. Concord Biotech Limited is an India-based research and development driven biopharma company. The firm is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The firm manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic processes and finished formulations. The company manufactures fermentation and semi-synthetic based products in the therapeutic segments, such as immunosuppressants, anti-bacterial, oncology, anti-fungal and others. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Vancomycin Hydrochloride, Micafungin Sodium, Mupirocin, Romidepsin, Dactinomycin, and Pravastatin Sodium, among others. The company also has a pipeline of API products under development. Its API products under development include Polymyxin B, Fidaxomicin, Doxorubicin, and others. The firm provides products in the critical care, immunology, nephrology, and transplant medicine segments.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹1,055 Cr revenue.
COGS 23.3%, employees 16.8%.
“We believe that this is just a timing difference and postponement of sales and not loss of business.”
“Excluding these initial start up costs, our Amrita margin stood at 41%.”
“6%. 76%.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 12.9%▲ | 10.3% |
| ROCE | 16.6%▲ | 13.7% |
| Net Margin | 23.6%▲ | 7.6% |
| EBITDA Margin | 37.6%▲ | 15.4% |
| Debt To Equity | 0.00x▼ | 0.15x |
| (₹ Cr) | TTM | FY2025 | FY2024 |
|---|---|---|---|
| Revenue | ₹1,055 Cr -12.1% | ₹1,200 Cr +18.0% | ₹1,017 Cr |
| Other Income | ₹52 Cr +17.8% | ₹44 Cr +31.6% | ₹34 Cr |
| Total Income | ₹1,107 Cr -11.0% | ₹1,245 Cr +18.4% | ₹1,051 Cr |
| COGS | ₹246 Cr -19.6% | ₹306 Cr +33.3% | ₹229 Cr |
| ₹762 Cr +1.8% | ₹749 Cr +16.7% | ₹642 Cr | |
| Profit Before Tax | ₹342 Cr -31.1% | ₹496 Cr +21.2% | ₹409 Cr |
| Exceptional Items | (₹3 Cr) | ₹0.00 Cr | ₹0.00 Cr |
| ₹85 Cr -30.5% | ₹123 Cr +17.7% | ₹104 Cr | |
| Net Profit | ₹259 Cr -30.2% | ₹372 Cr +20.6% | ₹308 Cr |
| Profit (Owners) | ₹261 Cr -29.8% | ₹372 Cr +20.6% | ₹308 Cr |
| Minority Interest | (₹2 Cr) | ₹0.00 Cr | ₹0.00 Cr |
| Other Comprehensive Income | ₹55 Cr +825.5% | ₹6 Cr ↑ Recovery | (₹0.01 Cr) |
| EPS | ₹24.94 | ₹35.52 | ₹29.45 |
| Diluted Shares | ₹10 Cr | ₹10 Cr | ₹10 Cr |
| Profit Or Loss Of Associates | ₹3 Cr ↑ Recovery | (₹1 Cr) ↓ Decline | ₹3 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Concord Biotech Limited has informed the Exchange about Schedule of meet
Concord Biotech Limited has informed the Exchange about Copy of Newspaper Publication
Concord Biotech Limited has informed the Exchange that Record date for the purpose of Dividend & Meeting is 24-Jul-2026.
Concord Biotech Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on July 31, 2026
Concord Biotech Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Concord Biotech Limited has informed the Exchange about Schedule of meet
Concord Biotech Limited has informed the Exchange about Schedule of meet
Concord Biotech Limited has informed the Exchange regarding 'Completion of ANVISA Inspection conducted by the Brazilian Health Regulatory Agency at the Limbasi API Manufacturing Facility'.
Concord Biotech Secures Abbreviated New Drug Application (ANDA) Approval for Tofacitinib Tablets, 5 mg and 10 mg
Concord Biotech Limited has informed the Exchange regarding Abbreviated New Drug Application (ANDA) Approval for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL'.
Concord Biotech Limited has informed the Exchange about Investor Presentation
Concord Biotech Limited has informed the Exchange about Copy of Newspaper Publication
Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Concord Biotech Limited has informed the Exchange about Schedule of meet
Concord Biotech Limited has informed the Exchange about Schedule of meet